Basic research on development of dendritic cell therapy targeting glioma cancer stem cells

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10346
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Kansai Medical University
• Principal Investigator: ASAI Akio 関西医科大学, 医学部, 教授 (50231858)
• Co-Investigator(Kenkyū-buntansha): 岩田 亮一 関西医科大学, 医学部, 助教 (60580446) ; 伊藤 量基 関西医科大学, 医学部, 准教授 (70434826)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: グリオーマ / 膠芽腫 / 癌幹細胞 / 樹状細胞 / 免疫抑制 / 免疫治療 / テモゾロミド

Outline of Final Research Achievements

Glioblastoma multiforme (GBM) is the most fatal malignant primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. We established GSCs lines and analyzed the expression of immune-associated molecules. GSCs lines were positive for MHC-Ⅰ, which indicated that GSCs can be recognized by T cells. Temozolomide (TMZ) is an oral alkylating agent with established anti-tumor activity in patients with GBM. We focused on the TMZ function and explored its influence on human dendritic cells (DCs) subsets. TMZ suppressed the secretion of IL-10 from DCs. Moreover, the addition of TMZ into peripheral blood mononuclear cells with DCs significantly enhanced the DC mediated ex vivo expansion and expression of cytotoxic molecules in CD8+ T cells. Our present findings suggest that TMZ is a potential anti-tumor reagent suitable for the combination use with DC-vaccine therapy.

Free Research Field

医学